Cambrex, Snapdragon Chemistry, and Q1 Scientific recognized for innovation and sustainability in Pharma. July 7, 2026 EAST RUTHERFORD, N.J., July 7, 2026 /PRNewswire/ - Cambrex, a leading global contract development and manufacturing organization (CDMO), proudly announces that Snapdragon Chemistry, a Cambrex company, together with NewAmsterdam Pharma, has received the American Chemical Society's 2026 Green Chemistry Challenge Award for the Greener Synthetic Pathway in the Synthesis of Pharmaceuticals. The award recognizes the companies' successful development of a sustainable organocatalytic process to manufacture the chiral tetrahydroquinoline core for the synthesis of obicetrapib, a late-stage investigational therapy for dyslipidemia. NewAmsterdam Pharma, in collaboration with Snapdragon Chemistry, developed an industrial-scale synthesis of an organocatalyzed asymmetric Povarov cyclization to manufacture the chiral tetrahydroquinoline core, a key intermediate in the synthesis of obicetrapib. Compared with the previous manufacturing route, the organocatalytic process significantly improved overall efficiency and sustainability, delivering substantial gains in yield, reducing process mass intensity by approximately 80%, eliminating aqueous waste generation, shortening manufacturing cycle time by approximately 70% and lowering manufacturing costs by approximately 50%. Furthering its sustainability leadership, Cambrex's Milan facility has been awarded the EcoVadis Gold rating, placing it among the top 5% of organizations evaluated for environmental, social and ethical performance. This distinction reflects Cambrex's comprehensive sustainability strategy, including a 20% reduction in greenhouse gas emissions network-wide and a goal to reduce emissions by 50% by 2030. Additionally, Q1 Scientific, a Cambrex company, has partnered with Flogas through a Corporate Power Purchase Agreement (CPPA) to source renewable electricity from the Cronalaght Wind Farm. This partnership will cover approximately 50% of the Q1 Scientific Waterford site's electricity demand, supporting both client and community environmental goals and reinforcing Cambrex's position as a responsible industry leader. Thomas Loewald, CEO at Cambrex commented, "At Cambrex, we are dedicated to continually reducing our environmental impact for the benefit of our communities and ensuring long-term, sustainable manufacturing solutions for our customers." About Cambrex Cambrex is a leading global contract development and manufacturing organization (CDMO) that provides drug substance development and manufacturing across the entire drug lifecycle, as well as comprehensive analytical services. With over 45 years of experience and a team of 2,000 experts servicing global clients from North America and Europe, Cambrex offers a range of specialized drug substance technologies and capabilities, including continuous flow, controlled substances, peptide synthesis, solid-state science, biocatalysis, material characterization, complex synthetics, and highly potent APIs.

NewAmsterdam Pharma announces upcoming presentations at the National Lipid Association (NLA) 2026 Scientific Sessions. NAARDEN, The Netherlands and MIAMI, June 03, 2026 (GLOBE NEWSWIRE) - NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or "NewAmsterdam" or the "Company"), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of cardiovascular disease ("CVD") with elevated low-density lipoprotein cholesterol ("LDL-C"), for whom existing therapies are not sufficiently effective or well-tolerated, today announced that it will present data highlighting the potential for obicetrapib as a novel, oral, low-dose therapy for hypercholesterolemia, at the National Lipid Association (NLA) 2026 Scientific Sessions, taking place on June 11 - 14, 2026 in Chicago, Illinois. Presentation details are as follows: Title: Novel Cholesterol Lowering Drugs: Can phase 2/3 clinical trial safety assessments predict cardiovascular event outcome trial efficacy? Abstract Number: 353 Date and Time: Friday, June 12, 2026 at 3:50 PM CDT Location: Kiosk #35 Presenter: Charles Shear Title: Mediation Analysis on LDL-C and LPa from Pooled Broadway and Brooklyn MACE Data Abstract Number: 220 Date and Time: Friday, June 12, 2026 at 10:30 AM CDT Location: Kiosk #35 Presenter: Michael Szarek, Ph.D. Title: Safety of Obicetrapib: An Integrated Phase III Safety Analysis Abstract Number: 165 Date and Time: Friday, June 12, 2026 at 10:30 AM CDT Location: Kiosk #4 Presenter: Adam J. Nelson, Ph.D. Title: CETP Inhibition With Obicetrapib Preserved Kidney Function in Patients at High Cardiovascular Risk: Results From the BROADWAY Trial Abstract Number: 182 Date and Time: Friday, June 12, 2026 at 1:50 PM CDT Location: Kiosk #40 Presenter: Liffert Vogt, M.D., Ph.D. Title: Pharmacokinetics and Safety of Obicetrapib in Moderate Hepatic Impairment: Phase I Study Results Abstract Number: 249 Date and Time: Friday, June 12, 2026 at 3:50 PM CDT Location: Kiosk #4 Presenter: John Kastelein, M.D., Ph.D., FESC, Chief Scientific Officer, NewAmsterdam Pharma Title: Obicetrapib CETP inhibition remodels HDL2 and raises ApoM, S1P, ApoA1 monomers, boosting plasma xanthophyll and carotenoid levels Abstract Number: 251 Date and Time: Friday, June 12, 2026 at 1:50 PM CDT Location: Kiosk #55 Presenter: Eric J. Niesor, Ph.D. Title: Cardiovascular Events in People with Normal Low-Density Lipoprotein Cholesterol Levels but Discordantly High Levels of Small/Medium LDL Particles Abstract Number: 262 Date and Time: Friday, June 12, 2026 at 3:50 PM CDT Location: Kiosk #43 Presenter: Floriaan Schmidt, Ph.D. Title: Intolerance and Adverse Events with High-Intensity Statin Therapy in Real-World Practice Abstract Number: 322 Date and Time: Friday, June 12, 2026 at 1:50 PM CDT Location: Kiosk #7 Presenter: Jennifer A. Kammerer, Pharm.D., MMI, CPHIMS, Director, HEOR Research, NewAmsterdam Pharma Title: Suboptimal Adherence and LDL-C Goal Attainment with High Intensity versus Moderate to-Low Intensity Statins in Real-World Practice Abstract Number: 323 Date and Time: Friday, June 12, 2026 at 3:50 PM CDT Location: Kiosk #7 Presenter: Jennifer A. Kammerer, Pharm.D., MMI, CPHIMS, Director, HEOR Research, NewAmsterdam Pharma About Obicetrapib Obicetrapib is a novel, oral, low-dose CETP inhibitor that NewAmsterdam is developing to overcome the limitations of current LDL-lowering treatments. In each of the Company's Phase 2 trials, ROSE2, TULIP, ROSE, and OCEAN, as well as the Company's Phase 3 BROOKLYN, BROADWAY and TANDEM trials, evaluating obicetrapib as monotherapy or combination therapy, the Company observed statistically significant LDL-lowering combined with a side effect profile similar to that of placebo. The Company commenced the Phase 3 PREVAIL cardiovascular outcomes trial in March 2022, which is designed to assess the potential of obicetrapib to reduce occurrences of MACE. The Company completed enrollment of PREVAIL in April 2024 and randomized over 9,500 patients. Commercialization rights of obicetrapib in Europe, either as a monotherapy or as part of a fixed-dose combination with ezetimibe, have been exclusively granted to the Menarini Group, an Italy-based, leading international pharmaceutical and diagnostics company. About NewAmsterdam NewAmsterdam Pharma (Nasdaq: NAMS) is a late-stage biopharmaceutical company whose mission is to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. NewAmsterdam Pharma Company seek to fill a significant unmet need for a safe, well-tolerated and convenient LDL-lowering therapy. In multiple phase 3 trials, NewAmsterdam is investigating obicetrapib, an oral, low-dose and once-daily CETP inhibitor, alone or as a fixed-dose combination with ezetimibe, as LDL-C lowering therapies to be used as an adjunct to statin therapy for patients at risk of CVD with elevated LDL-C, for whom existing therapies are not sufficiently effective or well tolerated. Investor Contact Precision AQ on behalf of NewAmsterdam Austin Murtagh P: 1-212-698-8696 [email protected]

NewAmsterdam Pharma has raised $120 million in a Series C round led by Ribbit Capital, valuing the pre-revenue AI startup at $1.45 billion. Sequoia, Kleiner Perkins and newcomer Emerson Collective participated in the funding. Co-founded by Robinhood CEO Vlad Tenev, Harmonic develops "Mathematical Superintelligence" aimed at eliminating AI hallucinations through formal reasoning. Its Aristotle model requires outputs in Lean4 programming language, enabling verification for correctness. The model achieved top performance at the International Mathematical Olympiad in July. Founded in 2023, Harmonic has raised $295 million across three rounds in 14 months. The company offers Aristotle via free API and plans to commercialise in safety-critical sectors including aerospace and finance. Most funding will support computing power for model training.